Data Show Progression-Free Survival Advantage With Sutent(R) In Patients With Pancreatic Neuroendocrine Tumors

Pfizer Inc. announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas…

More: continued here

Filed under: Cancer on January 25th, 2010